Global Somatropin Market
The global Somatropin market was valued at USD 5,582.1 million in 2020 and is expected to reach USD 8,610.8 million by 2027, growing at a CAGR of 6.39% from 2020 to 2030.
In terms of application, the worldwide industry is categorized into Growth Hormone Deficiency (GHD), Turner Syndrome, Chronic Rental Insufficiency, Prader Willi Syndrome, SHOX Deficiency and others.
The Growth Hormone Deficiency (GHD) application segment is estimated to be the highest share of the somatropin market in 2019. Factors such as rising cases of growth hormone deficiencies and increasing awareness are major driving factors for the segment.
Market Drivers
Increasing Prevalence of Growth Hormone Deficiencies
Challenges:
High cost and side effects of therapies
North America is expected to account for the major share due to factors such as established healthcare infrastructure, promising reimbursement scenario, substantial government initiatives, and rising healthcare awareness. Besides, augmented access to innovative drugs owing to the existence of main players in North America supports the regional market.
Recent Development:
In November 2020: Emisphere Technologies, Inc. announced that it has entered into a definitive agreement with Novo Nordisk A/S (“Novo Nordisk”), whereby Novo Nordisk will acquire Emisphere, on a cash-free, debt-free basis, for $1.35 billion in cash.
In December 2020: Eli Lilly and Company and UnitedHealth Group announced a partnership to conduct a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals.
Market Key Players
Various key players are discussed in this report such as Novo Nordisk A/S, Eli Lilly and Company, Pfizer, Inc., GeneScience Pharmaceuticals, Ipsen Inc.,Sandoz International, LG Life Sciences, Merck, Hoffmann-La Roche, and Teva Pharmaceuticals.
Market Taxonomy
By Dosage Form
By Application
By Distribution Channel
By Region
Key Questions Addressed by the Report
Global Somatropin Market TOC
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Somatropin Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Somatropin Market, By Dosage Form
5.1 Y-o-Y Growth Comparison, By Dosage Form
5.2 Global Somatropin Market Share Analysis, By Dosage Form
5.3 Global Somatropin Market Size and Forecast, By Dosage Form
5.3.1 Powder
5.3.2. Solvent
6 Global Somatropin Market, By Application
6.1 Y-o-Y Growth Comparison, By Application
6.2 Global Somatropin Market Share Analysis, By Application
6.3 Global Somatropin Market Size and Forecast, By Application
6.3.1Growth Hormone Deficiency (GHD)
6.3.2 Turner Syndrome
6.3.3 Prader Willi Syndrome
6.3.4 SHOX Deficiency
6.3.5 Others
7 Global Somatropin Market, By Distribution Channel
7.1 Y-o-Y Growth Comparison, By Distribution Channel
7.2 Global Somatropin Market Share Analysis, By Distribution Channel
7.3 Global Somatropin Market Size and Forecast, By Distribution Channel
7.3. 1 Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
8 Global Somatropin Market, By Region
8.1 Global Somatropin Market Share Analysis, By Region
8.2 Global Somatropin Market Share Analysis, By Region
8.3 Global Somatropin Market Size and Forecast, By Region
9 North America Somatropin Market Analysis and Forecast (2021-2030)
9.1 Introduction
9.2 North America Somatropin Market Share Analysis, By Dosage Form
9.3 North America Somatropin Market Size and Forecast, By Application
9.4 North America Somatropin Market Size and Forecast, By Distribution Channel
9.5 North America Somatropin Market Size and Forecast, By Country
9.5.1 U.S.
9.5.2 Canada
9.5.3 Mexico
10 Europe Somatropin Market Analysis and Forecast (2021-2030)
10.1 Introduction
10.2 Europe Somatropin Market Share Analysis, By Dosage Form
10.3 Europe Somatropin Market Size and Forecast, By Application
10.4 Europe Somatropin Market Size and Forecast, By Distribution Channel
10.5 Europe Somatropin Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.54. Rest of Europe
11 Asia Pacific Somatropin Market Analysis and Forecast (2021-2030)
11.1 Introduction
11.2 Asia Pacific Somatropin Market Share Analysis, By Dosage Form
11.3 Asia Pacific Somatropin Market Size and Forecast, By Application
11.4 Asia Pacific Somatropin Market Size and Forecast, By Distribution Channel
11.5 Asia Pacific Somatropin Market Size and Forecast, By Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4. Rest of Asia Pacific
12 Latin America Somatropin Market Analysis and Forecast (2021-2030)
12.1 Introduction
12.2 Latin America Somatropin Market Share Analysis, By Dosage Form
12.3 Latin America Somatropin Market Size and Forecast, By Application
12.4 Latin America Somatropin Market Size and Forecast, By Distribution Channel
12.5 Latin America Somatropin Market Size and Forecast, Country
13 Middle East Somatropin Market Analysis and Forecast (2021-2030)
13.1 Introduction
13.2 Middle East Somatropin Market Share Analysis, By Dosage Form
13.3 Middle East Somatropin Market Size and Forecast, By Application
13.4 Middle East Somatropin Market Size and Forecast, By Distribution Channel
13.5 Middle East Somatropin Market Size and Forecast, By Country
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 Novo Nordisk A/S
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2. Eli Lilly and Company
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3. Pfizer, Inc
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 GeneScience Pharmaceuticals
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Ipsen Inc
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Sandoz International
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 LG Life Sciences
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Merck
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 Hoffmann-La Roche
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 Teva Pharmaceuticals
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies
